Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 13 January 2012 | By Alexander Gaffney, RAC
The Energy and Commerce Committee of the US House of Representatives announced Thursday that its Health Subcommittee will hold hearings on the Prescription Drug User Fee Act (PDUFA) reauthorization, Medical Device Use Fee (MDUFA) Act reauthorization, and the authorization of the Generic Drug User Fee Act (GDUFA).
The subcommittee will hold its first hearing on PDUFA on 1 February and call US Food and Drug Administration (FDA) Commissioner Margaret Hamburg to testify.
The subcommittee will hold a second hearing on 7 February to discuss the authorization of GDUFA, and will call Center for Drug Evaluation and Research Director Janet Woodcock to testify.
The subcommittee will hold a final hearing on 15 February regarding MDUFA, and call Center for Devices and Radiological Health Director Jeffery Shuren to testify.
PDUFA and MDUFA are both set to expire in September, making the prospect of any slowdown a dangerous one for FDA and pharmaceutical industry alike. FDA is expected to issue final recommendations on the PDUFA legislation on 15 January.
The legislation would cover FY2013-2017 and require more communication between FDA and industry.
Tags: Margaret Hamburg, Testify, Hearing, Authorization, House, Law, Janet Woodcock, Reauthorization, MDUFA, Latest News, Jeffery Shuren, GDUFA, PDUFA